##  [What is Lifecycle Management in the TGA Regulatory Framework?](/index%2ephp/what-is-lifecycle-management-in-the-tga-regulatory-framework) 

1 min read 

 Your browser does not support the audio element.





For pharmaceutical and medical device companies entering the Australian market, getting a product approved by the **Therapeutic Goods Administration (TGA)** is a major milestone — but it’s far from the finish line.

That’s where **Lifecycle Management (LCM)** comes in.

Lifecycle Management in the TGA context refers to the **ongoing regulatory activities that ensure a product remains compliant throughout its time on the market**. Once included in the **Australian Register of Therapeutic Goods (ARTG)**, every change to the product — be it formulation, labeling, manufacturing site, or packaging — must be managed in accordance with TGA’s defined post-approval frameworks.

This includes:

- **Variations:** Managing major and minor changes (Category 1, Category 3, or self-assessable).
- **Renewals:** Maintaining valid GMP clearances and periodic license updates.
- **Post-approval updates:** Keeping CMC data, labeling, and safety information current.

Effective lifecycle management ensures **sustained market access**, **regulatory compliance**, and **patient safety**. It also minimizes the risk of ARTG suspension or product recall — critical for maintaining business continuity.

In a rapidly evolving regulatory landscape, a proactive post-approval strategy is no longer optional; it’s essential.

Freyr’s **Australia office** supports global and local companies in building compliant, efficient LCM frameworks aligned with TGA and ICH standards. From dossier variations to renewal management and labeling updates, **Freyr ensures your compliance never lapses.**

**Read the full article:** Lifecycle Management & Post-Approval Strategy: Sustaining TGA Compliance in Australia’s Pharma Market